Loading
A phase 2 trial of QLS32015, Pomalidomide, Dexamethasone in multiple myeloma, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma is a phase 2 interventional study registered as NCT07018050 by Qilu Pharmaceutical Co., Ltd., with 160 participants planned, started 2025-09-12 and due to reach its primary completion in 2027-11. Interventions recorded: QLS32015, Pomalidomide, Dexamethasone, QL2109 or Daratumumab, Bortezomib. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QLS32015, Qilu Pharmaceutical, Multiple myeloma.
Shares Pomalidomide, Bortezomib, Lenalidomide, Dexamethasone.
Shares Bortezomib, Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Shares Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/